
A study revealed promising results for RGRN-305, a potential treatment for moderate to severe Hidradenitis Suppurativa. The study demonstrated a 60% success rate in achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR-50) at week 16 with RGRN-305 compared to 20% in the placebo group. The novel heat shock protein 90 inhibition mechanism proves well-tolerated, marking a significant step toward addressing the limited treatment options for this painful immune-mediated disorder.
Like
Save
Share